Rapport Therapeutics Soars 119% on $480M Volume Ranks 235th in Market Activity Amid Promising Trial Results

, 2025, , ranking 235th in market activity. The rally followed positive Phase 2a trial results for its experimental drug RAP-219 in treating drug-resistant focal onset seizures.

The clinical-stage biotech reported the trial met its primary endpoint, . , . CEO highlighted the drug’s potential as a first-in-class treatment, noting its favorable tolerability profile, with mild to moderate side effects like dizziness and fatigue reported.

Rapport plans to advance RAP-219 into two Phase 3 trials in Q3 2026 after an end-of-Phase 2 meeting with the FDA in late 2025. The company is also evaluating a long-acting formulation and a Phase 2 trial for bipolar mania, with results expected in mid-2027. The trial leveraged the ’s intracranial EEG data to measure seizure activity, offering a more precise metric than traditional methods.

To run this back-test accurately I need to pin down a few practical details: Stock universe – should we rank all U.S. listed equities every day, or a particular index membership (e.g., S&P 1500)? Trade timing – do you want to: buy the 500 highest-volume names at that day’s close and sell them the next day’s close, or buy at the next day’s open and sell that day’s close? Any preferences on transaction costs or position sizing (equal-weight vs. volume-weighted)? Once these are set I can generate the data-gathering plan and launch the back-test.